Challenges in accurate registration of 3-D medical imaging and histopathology in primary prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue SUPPL. 1, 2013, Pages

  Meyer, Charles ^a   Ma, Bing ^a   Kunju, Lakshmi P ^b   Davenport, Matthew ^a   Piert, Morand ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Computer aided design; Mutual information; Primary prostate cancer; Registration of 3 D medical imaging onto pathology

Indexed keywords

ARTICLE; CANCER REGISTRY; CLINICAL PRACTICE; DIAGNOSTIC IMAGING; HISTOPATHOLOGY; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY TUMOR; PROSTATE CANCER; PROSTATECTOMY; STANDARD; THREE DIMENSIONAL IMAGING; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC ERROR; MALE; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; REVIEW; PROCEDURES; PROSTATIC NEOPLASMS; STANDARDS;

DIAGNOSTIC ERRORS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; PROSTATIC NEOPLASMS;

EID: 84891598134     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2382-2     Document Type: Article

References (30)

1. American Cancer Society. Cancer facts and figures 2012. Atlanta: American Cancer Society; 2012
2. Bill-Axelson A, Holmberg L, Filen F, RuutuM, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100:1144-54.
3. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol. 1998;160:2407-11.
4. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368-74.
5. Karavitakis M, Ahmed HU, Abel PD, Hazell S, Winkler MH. Tumor focality in prostate cancer: implications for focal therapy. Nat Rev Clin Oncol. 2011;8:48-55.
6. Farsad M, Schwarzenbock S, Krause BJ. PET/CT and choline: diagnosis and staging. Q J NuclMedMol Imaging. 2012;56:343-53.
7. Li X, Liu Q,Wang M, Jin X, Yao S, Liu S, et al. C-11 choline PET/ CT imaging for differentiating malignant from benign prostate lesions. Clin Nucl Med. 2008;33:671-6.
8. 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med. 2009;50:1585-93.
9. 11C-choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness. Radiol Oncol. 2012;46:179-88.
10. 11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med. 2012;53:538-45.
11. Cohen MS, Hanley RS, Kurteva T, Ruthazer R, Silverman ML, Sorcini A, et al. Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol. 2008;54:371-81.
12. Orczyk C, Mikheev A, Rosenkrantz A, Melamed J, Taneja SS, Rusinek H. Imaging of prostate cancer: A platform for 3D co-registration of in-vivo MRI ex-vivo MRI and pathology. Proc SPIE. 2012;8316:83162M
13. Jonmarker S, Valdman A, Lindberg A, Hellstrom M, Egevad L. Tissue shrinkage after fixation with formalin injection of prostatectomy specimens. Virchows Arch. 2006;449:297-301.
14. Schned AR,Wheeler KJ, Hodorowski CA, Heaney JA, ErnstoffMS, Amdur RJ, et al. Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol. 1996;20:1501-6.
15. Kim B, Boes JL, Frey KA, Meyer CR. Mutual information for automated unwarping of rat brain autoradiographs. Neuroimage. 1997;5:31-40.
16. Balter JM, Sandler HM, Lam K, Bree RL, Lichter AS, Ten Haken RK. Measurement of prostate movement over the course of routine radiotherapy using implanted markers. Int J Radiat Oncol Biol Phys. 1995;31:113-8.
17. Dinkel J, Thieke C, Plathow C, Zamecnik P, Prum H, Huber PE, et al. Respiratory-induced prostate motion: characterization and quantification in dynamic MRI. Strahlenther Onkol. 2011;187:426-32.
18. Malone S, Crook JM, Kendal WS, Szanto J. Respiratory-induced prostate motion: quantification and characterization. Int J Radiat Oncol Biol Phys. 2000;48:105-9.
19. Udrescu C, Jalade P, de Bari B, Michel-Amadry G, Chapet O. Evaluation of the respiratory prostate motion with four-dimensional computed tomography scan acquisitions using three implanted markers. Radiother Oncol. 2012;103:266-9.
20. Park H, Piert MR, Khan A, Shah R, Hussain H, Siddiqui J, et al. Registration methodology for histological sections and in vivo imaging of human prostate. Acad Radiol. 2008;15:1027-39.
21. Zachariah CR, Pitt D,Wassenar P, Clymer BD, Abduljalil AM, Knopp MV, et al. Quantification of formalin-fixed MS brain tissue parameters T1, T2*, PD and phase at 7T and comparison with histopathology. Proceedings of the Annual Meeting of the International Society for Magnetic Resonance in Medicine; 2010 May 1-7; Stockholm, Sweden. Berkeley: International Society for Magnetic Resonance in Medicine; 2010. p. 2073.
22. 11C-choline PET/CT of human prostate cancer using multimodality fusion techniques. Acad Radiol. 2010;17:614-23.
23. Park H, Wood D, Hussain H, Meyer CR, Shah RB, Johnson TD, et al. Introducing Parametric Fusion PET/MRI of Primary Prostate Cancer. J Nucl Med Mol Imaging. 2012;53:546-51.
24. 18F-FAZA PET/CT utilizing multimodality fusion techniques. Eur J Nucl Med Mol Imaging. 2011;38:1816-23.
25. Drew B, Jones EC, Reinsberg S, Yung AC, Goldenberg SL, Kozlowski P. Device for sectioning prostatectomy specimens to facilitate comparison between histology and in vivo MRI. J Magn Reson Imaging. 2010;32:992-6.
26. Chen LH, Ho H, Lazaro R, Thng CH, Yuen J, Ng WS, et al. Optimum slicing of radical prostatectomy specimens for correlation between histopathology and medical images. Int J Comput Assist Radiol Surg. 2010;5:471-87.
27. Shah V, Pohida T, Turkbey B, Mani H, Merino M, Pinto PA, et al. A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds. Rev Sci Instrum. 2009;80:104301.
28. Trivedi H, Turkbey B, Rastinehad AR, Benjamin CJ, Bernardo M, Pohida T, et al. Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer. Urology. 2012;79:233-9.
29. Fan X, Haney CR, Agrawal G, Pelizzari CA, Antic T, Eggener SE, et al. High-resolution MRI of excised human prostate specimens acquired with 9.4T in detection and identification of cancers: validation of a technique. J Magn Reson Imaging. 2011;34:956-61.
30. Meyer CR, Wahl RL. Image fusion. In: Wahl RL, editor. Principle and practices of PET and PET/CT. 2nd ed. Philadelphia: Williams and Wilkins; 2009. p. 111-6.